EU Invests in Neurotechnology: A New Era for Brain Health
Europe is poised to become a global leader in neurotechnology, a rapidly advancing field with the potential to revolutionize the treatment of neurological and mental health conditions. Despite its growing significance, neurotechnology has historically received limited attention and specialized funding within the European Union’s Horizon Europe program. Now, a push for a more strategic approach, coupled with lessons from initiatives like the UK’s Advanced Research and Innovation Agency (Aria), is gaining momentum.
The Promise of Neurotechnology
Neurotechnology encompasses technologies and techniques that interact directly with the human nervous system. This includes both invasive methods, such as deep brain stimulation, and non-invasive techniques like transcranial magnetic stimulation. These advancements offer potential solutions for conditions resistant to traditional treatments, including major depressive disorder, epilepsy, Parkinson’s disease, and chronic pain. For example, one-third to one-half of individuals with major depressive disorders do not respond to multiple antidepressants, highlighting the need for alternative approaches.
A Growing Global Race
The development of neurotechnology is becoming increasingly competitive on a global scale. OpenAI’s co-funding of the brain-computer interface start-up Merge Labs, valued at $850 million, and China’s ambition to lead in brain-computer interface technology by 2030 demonstrate the growing international interest. Europe, however, has a strong foundation in neurotechnology research, with pioneering work originating from institutions like the Grenoble University Hospital in France, where Alim-Louis Benabid’s research on deep brain stimulation significantly improved the lives of Parkinson’s disease patients.
European Centers of Excellence
Numerous centers of excellence in neurotechnology are located across Europe, including the Paris Brain Institute, the Netherlands Institute of Neuroscience, Universidad Politécnica de Madrid, CEA-Leti, and École Polytechnique Fédérale de Lausanne. These institutions are working on diverse applications, such as spinal cord stimulation, blocking pathological activity, and methods to repair brain tissue damaged by trauma or stroke.
Addressing the Funding Gap
Currently, neurotechnology innovators often compete for funding in broad, undifferentiated streams within Horizon Europe, receiving less of the specialized support needed for this complex field. This structural mismatch hinders the field’s progress. The EU needs to maximize pre-competitive collaboration to ensure synergies across research efforts and fully realize innovation opportunities.
A Three-Pronged Approach to Success
To unlock the full potential of neurotechnology, a three-pronged approach is necessary:
- Maximize Collaboration: Foster pre-competitive collaboration to create synergies and realize innovation opportunities.
- Dedicated Funding Board: Establish a dedicated neurotechnology funding board to coordinate and optimize funding instruments.
- Healthcare Reimbursement Models: Develop neurotechnology-specific healthcare reimbursement models and enable resource pooling among member states for large-scale adoption.
Ethical Considerations and Responsible Development
As neurotechnology advances, it’s crucial to address the ethical implications surrounding privacy, agency, mental autonomy, human identity, consent, and equity. The European Charter for the Responsible Development of NeuroTechnologies encourages responsible and ethical development, regulatory mechanisms, and alignment with ethical principles among innovators.
Looking Ahead
The European Innovation Council (EIC) is preparing to launch Advanced Innovation Challenges for 2026-27 and should draw inspiration from the UK’s Aria. By adopting a more strategic approach, Europe can establish itself as a leader in neurotechnology, driving innovation, improving brain health, and addressing the growing global burden of neurological and mental health conditions. The field is projected to increase globally by 22% by 2050, with dementia expected to represent 11% of all healthcare spending in Germany by 2050.